Financial Statements

Supernus Pharmaceuticals, Inc. (SUPN)


+0.86 (+2.49%)
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers are in thousands , Years are calendar years not fiscal years

Retained Earning Schedule

Year 2022 2021 2020 2019 2018
Retained Earnings (Previous Year) 38032620086-
Net Income 6153127113111
Stock Dividends 41----25
Dividend Paid -----
Retained Earnings 48138032620086

PPE Schedule

Year 2022 2021 2020 2019 2018
Gross PPE 1738384-
Annual Depreciation -1-193375
Capital Expenditure -0-2-3-3-1
Net PPE 151738384

Intangible and Goodwill Schedule

Year 2022 2021 2020 2019 2018
Intangible and Goodwill (Previous Year) ---78118
New Purchases -492-410-96-312-407
Intangible and Goodwill --78118117

Supernus Pharmaceuticals, Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Supernus Pharmaceuticals, Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.